ODYSSEUS LUNAR LANDER TILTS, YET MAINTAINS OPERATIONAL POTENTIAL.
Intuitive Machines’ lunar lander, Odysseus, experienced a mishap during its touchdown near the moon’s south pole, ending up on its side due to coming in too fast and possibly breaking a leg upon impact. Despite this setback, CEO Steve Altemus reported that the lander retains significant operational capability. However, the positioning of some antennas towards the moon’s surface has limited data transmission back to Earth. The lander, part of a mission largely sponsored by NASA to jump-start lunar exploration and economy, is the first U.S. lander to reach the moon in over 50 years and marks Intuitive Machines as the first private company to achieve a moon landing. The mission faced challenges, including a navigation system issue resolved by a last-minute switch to a NASA laser system. The mission, which also included experiments such as the EagleCam, is expected to operate for about a week before the lunar nightfall. This event follows Astrobotic Technology’s attempt, which ended in failure due to a fuel leak, highlighting the challenges and achievements of private entities in lunar exploration. (Associated Press)
NEURALINK’S MIND-CONTROL DEVICE RAISES DOUBTS AMID ACHIEVEMENT.
Elon Musk’s company, Neuralink, has made headlines with its brain-monitoring device, enabling a person to control a computer cursor with their mind. Despite the achievement, experts express skepticism about the novelty and are concerned about the lack of transparency regarding the device’s safety and efficacy. Neuralink’s device, which features 1,024 electrodes on flexible threads, stands out for its ability to record individual neuron activity, a significant advancement over previous systems. However, the ability to control a cursor through thought is not unprecedented, with similar feats achieved by other companies and research dating back to 2004. Critics emphasize the need for more information on Neuralink’s trials, particularly regarding safety and the surgical procedure’s specifics. While the development is seen as a step forward for brain-computer interface technology, the ultimate goals and potential of Neuralink’s device remain subjects of both interest and concern within the scientific community. (Nature)
If you’re enjoying the Daily Dose, sign up for the Daily Dose Newsletter and get the morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.
XOLAIR: BREAKTHROUGH IN REDUCING SEVERE FOOD ALLERGY REACTIONS.
Xolair, a drug traditionally used for treating allergic asthma and hives, has shown promise in significantly reducing the risk of severe allergic reactions in children with food allergies to peanuts, cashews, milk, and eggs. This was revealed in a study published in The New England Journal of Medicine and presented at the American Academy of Allergy, Asthma and Immunology’s annual conference. The Food and Drug Administration has approved Xolair for adults and children over one year old with food allergies, marking it as the first treatment to greatly lower the danger of anaphylaxis from accidental exposure to various allergens. The study, a double-blind, randomized, placebo-controlled clinical trial—the gold standard in medical research—included 177 participants aged 1 to 17 who were allergic to multiple foods. Results showed a significant percentage of those treated with Xolair could tolerate higher amounts of allergens without severe symptoms, compared to those who received a placebo. Despite its effectiveness in reducing reaction risks, Xolair does not cure allergies and requires regular injections, making it less than a perfect solution. Yet, for many, it offers a new layer of protection against the risks of accidental exposure, potentially changing the lives of those with severe food allergies. (New York Times)
NHS TRIAL SHOWS PROMISING RESULTS WITH CYTOSPONGE FOR OESOPHAGEAL CANCER.
The NHS’s trial of an innovative “cytosponge” method is showing promise in identifying Barrett’s oesophagus, a precursor to oesophageal cancer, thus reducing the need for endoscopies. This non-invasive test involves swallowing a capsule that expands into a sponge in the stomach and is then retrieved, collecting cells for analysis. Out of 8,500 patients tested in England, 78% were found not to require further endoscopic examination, significantly easing the demand on the NHS’s endoscopy services. This method not only accelerates the diagnostic process for patients at higher risk of oesophageal cancer but also offers a cost-effective, less invasive, and quicker alternative to traditional endoscopy, costing the NHS £300 less per test. The cytosponge has been used in 30 hospitals since 2021, contributing to reduced waiting times for endoscopies and potentially leading to earlier detection of oesophageal cancer, which is critical given the disease’s high mortality rate in the UK. (The Guardian)
CONTROVERSY OVER NATURE PUBLICATION SPARKS DEBATE ON GENETIC REPRESENTATION.
A controversy erupted on social media regarding a Nature publication on the All of Us research project, aimed at capturing the genetic diversity across the U.S. by sequencing nearly 250,000 genomes. Critics argued that a figure in the paper might misleadingly suggest that humans fall into distinct racial categories, sparking debate over how human ancestry data is presented. The study’s leader, Josh Denny, acknowledged the constructive feedback, highlighting the evolving and complex nature of genetic research. Despite the critique, no immediate revision plans for the figure are disclosed. The All of Us project, which seeks to recruit 1 million volunteers, particularly from underrepresented groups, has identified over 1 billion DNA variants, enriching genomic research diversity. The contentious figure used an algorithm (UMAP) to represent genetic variations among participants, criticized for potentially oversimplifying genetic relationships and misrepresenting race. The incident underscores the challenges of conveying complex genomics data and the importance of carefully choosing ancestry labels in research. (Science)
JOHNSON & JOHNSON CLOSES R&D FACILITY IN BRISBANE.
Johnson & Johnson is shutting down its R&D facility in Brisbane, California, which spans nearly 200,000 square feet and was opened with enthusiasm less than 18 months ago. Despite the closure, J&J emphasizes its continued significant presence in California, including the establishment of a new Innovation Center. The decision to close the San Francisco Bay Campus (SFBC), communicated to employees recently, comes after a shift away from certain research priorities within the company’s pharma division, notably in infectious disease and vaccine research. The SFBC, which initially aimed to employ up to 400 people, focused on gene and RNA therapies, retinal, and infectious diseases research. However, internal shifts saw a gradual withdrawal from these areas. The closure follows J&J’s rebranding after spinning off its consumer health unit into Kenvue and amidst a record R&D expenditure of over $15 billion in 2023. The Brisbane site’s closure marks a significant scaling back from J&J’s ambitious R&D expansion in the Bay Area initiated with the campus’s opening. (Fierce Biotech)
JAPAN’S SLIM MOON LANDER SURVIVES HARSH LUNAR NIGHT.
Japan’s Moon lander, SLIM (Smart Lander for Investigating Moon), successfully rebooted itself after surviving the extremely cold lunar night, a period equivalent to two Earth weeks without sunlight, according to Japan’s national space agency, JAXA. Initially, after an awkward landing in January that misaligned its solar panels, SLIM faced power generation issues. However, a subsequent change in sunlight direction enabled it to revive and transmit images back to Earth before entering sleep mode again during the lunar nightfall. This achievement, hailed as significant by Dr. Simeon Barber from the UK’s Open University, underscores the technological advancements necessary for enduring the lunar environment’s extremes, essential for future long-term missions. Despite the harsh temperatures fluctuating between over 100C at noon to -130C at night near the Moon’s equator, SLIM managed to re-establish communication, preparing for continued operations. This development marks JAXA as the fifth national space agency to achieve a soft lunar landing, highlighting the growing capabilities in space exploration. (BBC)
SNAKES’ RAPID EVOLUTIONARY SUCCESS: NEW STUDY UNVEILS INSIGHTS.
Snakes represent a unique and rapid evolutionary success within the reptilian branch, standing out for their incredible diversity and adaptation to various habitats. A recent study published in Science highlights snakes’ evolution as a result of a “singularity,” a concept where minor changes cumulate into significant, unexpected outcomes. This singularity has led to snakes evolving into new ecological niches and forms three times faster than their squamate relatives, with this burst of evolution happening mainly in the last 70 to 100 million years. Despite many reptiles evolving snake-like traits independently, none have diversified at the rate of snakes, which feed predominantly on vertebrates compared to the more insectivorous diet of lizards. The study, which involved new genetic sequences from over 1,000 species and data from nearly 7,000 reptiles, not only underscores the rapid pace of snake evolution but also highlights the vast unknowns in their biology and conservation needs. The research opens new avenues for understanding snake evolution and emphasizes the urgency in expanding our knowledge of biodiversity and ecosystem dynamics, especially in understudied regions like the tropics. (Popular Science)
Thanks for reading. Let’s be careful out there.
WORDS: The Biology Guy.
IMAGE CREDIT: Intuitive Machines.